Bravecto Plus Spot On Cat Flea,tick dewormer,heartworm, heart disease > One Dose

Bravecto Plus Spot On Cat Flea,tick dewormer,heartworm, heart disease > One Dose - Pet Shop Luna

MSD Animal Heath

€ 45.00 

Bravecto Plus Spot On Cat  1 pipette is a parasite for cats with or at risk of parasitic infestations mixed with ticks and fleas, gastrointestinal nematodes or cardiac worms. The veterinary medicinal product is only indicated when used against ticks or fleas and one or more of the other target parasites is indicated at the same time. For the treatment of tick and flea infestations in cats providing immediate and persistent killing (Ctenocephalides felis) and ticks (Ixodes ricinus) for 12 weeks. The fleas and ticks must attach to the host and start feeding to be exposed to the active substance. The product can be used as part of a treatment strategy for flea allergy dermatitis (DAP). For treatment of intestinal roundworm infections (stage IV larvae, adult and adult Toxocara cati) and hookworm larvae (stage IV larvae, immature adults and adults of Ancylostoma tubaeforme). For the prevention of heart disease Dirofilaria immitis for 8 weeks.

Active substances

Each ml of solution contains  flouriner and 1 moxidectin.
Each pipette contains:

Excipient (s):
Clear clear to yellow solution.


Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Mild and transient skin reactions at the site of application (alopecia, skin exfoliation and pruritus) have been commonly seen in clinical trials.
The following other undesirable effects have been observed less frequently in clinical trials shortly after dosing: dyspnoea following application site licking, hypersalivation, vomiting, haematemesis, diarrhea, lethargy, pyrexia, tachypnoea, mumps.
The frequency of adverse reactions is defined using the following convention:
Very common (more than 1 out of 10 treated animals experiencing side effects during treatment)
Common (more than 1 but less than 10 animals in 100 treated animals)
Uncommon (more than 1 but less than 10 animals in 1,000 treated animals)
Rare (more than 1 but less than 10 animals out of 10,000 treated animals)
Very rare (less than 1 animal in 10,000 treated animals, including isolated reports).
If you notice any side effects, even those not already included in this leaflet or if you think the medicine has not been effective, please inform your veterinary surgeon.


For spot-on use.
Within each weight range, the contents of an entire pipette should be used.

Method of administration:
Step 1:

Immediately before use, open the envelope and remove the pipette.
Put the gloves. Pipettes must be held by the base or the upper rigid part under the lid in the upright position (upwards) to open.
The screwed cap must be rotated clockwise or counterclockwise, with a full turn.
The lid will remain on the pipette; it is not possible to remove it.
The pipettes are open and ready for application when the seal is broken.
Step 2:

The cat must be standing or stretched horizontally in order to be easy to apply.
Place the tip of the pipette at the base of the cat's skull.
Step 3:

Gently push the pipette and apply the whole contents directly to the cat's skin.
The product should be applied to cats up to 6.25 kg body weight in one place at the base of the skull and in two places at the base of the skull in cats greater than 6.25 kg body weight.

Treatment schedule:

For concomitant treatment of T. cati and A. tubaeforme gastrointestinal nematodes, a single dose of the product should be used.
The need for and the frequency of resumption of treatment should be in line with the opinion of the prescribing veterinarian and take into account the local epidemiological situation.
If necessary, cats can be re-treated at 12-week intervals.
Cats in endemic areas for heartworms or cats that have traveled to endemic areas may be infected with adult heartworms.


It's not necessary.

Keep out of the reach and sight of children.
This veterinary medicinal product does not require any special storage temperature.
Pipettes should be stored in envelopes to prevent solvent loss or moisture absorption.
Envelopes must be opened immediately before use.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiration date refers to the last day of that month.
Special precautions for each target species

Ticks and fleas must begin feeding on the host to be exposed to the flurry; therefore, the risk of transmitting diseases transmitted by the parasite can not be ruled out.
Cats in endemic areas for heartworms (or those that have traveled to endemic areas) may be infected with adult heartworms.
No therapeutic effect against adult Dirofilaria immitis has been demonstrated. It is therefore recommended, in accordance with good veterinary practice, that animals of 6 months of age or older who live in areas where a vector is present should be tested for existing infections with adult heartworms prior to the application of the veterinary medicinal product prevention of heart disease.
Prevention of heart disease in cats that are only temporarily in endemic areas The product should be applied before the first mosquito exposure. The period between treatment and return to a non-endemic area should not exceed 60 days.
For the treatment of infections with T. cati and A. tubaeforme gastrointestinal nematodes, the necessity and frequency of repetition of the treatment and the choice of treatment (monosubstance or combination product) should be evaluated by the attending veterinarian.
The resistance of parasites to any class of anthelmintics may occur after frequent and repeated use of an anthelmintic in that class under specific circumstances. The use of this veterinary medicinal product should be based on the assessment of each individual case and the local epidemiological information on the current susceptibility of the target species to limit the possibility of a future selection of resistance. Parasite control is recommended during the period of potential infection risk.
Avoid swimming or frequent shampooing, as maintaining product effectiveness in these cases has not been tested.
Special precautions for use in animals

Care should be taken to avoid contact of the product with the eyes of the animal.
Do not use directly on skin lesions.
In the absence of available data, cats less than 9 weeks old and cats less than 1.2 kg body weight are not recommended.
Treatment of male reproductive animals is not recommended.
This product is for topical use and should not be taken orally.
Oral ingestion of the product at the recommended maximum dose of 93 mg fluriner + 4.65 mg moxidectin / kg body weight resulted in an autoimmune salivation or a single episode of vomiting immediately after administration.
It is important to apply the dose as directed to prevent the animal licking and swallowing the product.
Do not allow recently treated animals to lick each other.
Do not allow treated animals to come into contact with untreated animals until the application site is dry.
Special precautions to be taken by the person administering the veterinary medicinal product to animals

This product is harmful if ingested. Keep the product in its original packaging until it is used to prevent children from directly accessing the product.
A used pipette should be discarded immediately. In case of accidental ingestion, seek medical advice and show the package leaflet or the label to your doctor.
The product is adherent to the skin and may also adhere to surfaces after drainage.
Rash, tingling or numbness have been reported in a small number of people after skin contact. Contact can occur either directly when handling the product or handling the treated animal. To avoid contact, single gloves
use must be worn when handling and administering the product.
If skin contact occurs, immediately wash the area with soap and water. In some cases, soap and water are not enough to remove the spilled product, so gloves should be used.
Make sure your animal's place of application is no longer visible before resuming contact with the application site. This includes kissing the animal and dividing the bed with the animal. It takes up to 48 hours for the application site to become dry, but more time will be visible.
If skin reactions occur, consult a physician and show the product packaging.

This product may cause eye irritation. In case of contact with eyes, rinse immediately with plenty of water.
Hypersensitivity reactions to another veterinary medicinal product containing fluralin and the same excipients as Bravecto Plus have been reported in a small number of people. The product should not be used by people who are hypersensitive to the active substance or any of the excipients (see contraindications). People with sensitive skin or known allergies, generally, e.g. other veterinary medicinal products of this type should carefully handle the veterinary medicinal product and the treated animals.
The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition.
In case of leakage on surfaces such as table or floor, remove excess product using paper and clean the area with detergent.
Gestation, lactation, fertility

The safety of the veterinary medicinal product has not been established during gestation and lactation and therefore use in such animals is not recommended.
Interactions with other medicinal products and other forms of interaction:

Macrocyclic lactones, including moxidectin, have been shown to be substrates for glycoprotein p. Therefore, during treatment with Bravecto Plus, other products that can inhibit p-glycoprotein (eg cyclosporine, ketoconazole, spinosad, verapamil may be used concomitantly depending on the risk-benefit assessment of the responsible veterinarian.
Overdosage (symptoms, emergency procedures, antidotes):

No adverse effects were observed after topical administration in kittens aged 9-13 weeks and body weight between 0.9-1.9 kg treated with overdoses of up to 5 times the maximum recommended dose (93 mg fluralin + 4, 65 mg moxidectin, 279 mg flouraner + 13.95 mg moxidectin and 465 mg fluralin + 23.25 mg moxidectin / kg body weight) three times at shorter intervals than recommended (8-week intervals).